The sodium salt of Ro 40-6890, used for susceptibility testing, has a broad-spectrum antimicrobial activity, including activity against aerobic gram-negative species (exclusive of Pseudomonas and Acinetobacter species) and aerobic and anaerobic gram-positive cocci (other than enterococci and oxacillin-resistant staphylococci) (1). These investigations also showed that Ro 41-3399 was approximately 50% bound to plasma proteins and was resistant to hydrolysis by broad-spectrum ,3-lactamases of types 2a, 2b, and 2c (2). In this report, we summarize the results of tests that defined the Ro 40-6890 spectrum of antimicrobial activity and present the preliminary determinations of disk diffusion test interpretive criteria with 5-, 10-, and 30-,ug Ro 40-6890 disks.
Ro 40-6890 (Hoffmann-La Roche, Basel, Switzerland) is the active free acid of the new orally absorbed cephalosporin ester, Ro 41-3399. This new cephalosporin has the chemical structure [ 
E]-2-(isobutoxycarbonyl)-2-pentenyl(6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetamido]-3-(azidomethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride (3)
. The sodium salt of Ro 40-6890, used for susceptibility testing, has a broad-spectrum antimicrobial activity, including activity against aerobic gram-negative species (exclusive of Pseudomonas and Acinetobacter species) and aerobic and anaerobic gram-positive cocci (other than enterococci and oxacillin-resistant staphylococci) (1) . These investigations also showed that Ro 41-3399 was approximately 50% bound to plasma proteins and was resistant to hydrolysis by broad-spectrum ,3-lactamases of types 2a, 2b, and 2c (2) . In this report, we summarize the results of tests that defined the Ro 40-6890 spectrum of antimicrobial activity and present the preliminary determinations of disk diffusion test interpretive criteria with 5-, 10-, and 30-,ug Ro 40-6890 disks.
Ro 40-6890 was provided by Hoffmann-La Roche, Ltd. Broth microdilution tests were performed in cation-supplemented Mueller-Hinton broth by dilution methods described by the National Committee for Clinical Laboratory Standards (5 Table 3 ; the absolute agreement ranged from 82 to 95.6%. There were very few very major or major errors with any of the disks or the various MIC breakpoint criteria. A >1% false-susceptible error rate (1.3%) was observed only with the 30-,ug disk and the MIC susceptibility breakpoint of (.0.5 ,ug/ml. No very major or major errors were observed with the 5-,ug disk and the MIC susceptibility breakpoint of c1 jig/ml (Table 3 and Fig. 1 ). The greatest absolute agreements (fewest total errors) were observed with the 10-,ug disk and the .2-jig/ml MIC susceptibility breakpoint (95.6%) and the 5-,ug disk and the 1-pg/ml MIC susceptibility breakpoint (94.9%).
These studies confirm the antimicrobial activities of this new cephalosporin. However, the clinical usefulness of Ro 41-3399 will ultimately be determined by the pharmacokinetics and safety of the orally administered formulation. Some strains of the Enterobactenaceae and some gram-positive species may not be inhibited if sustained levels in serum remain below 4 ,g/ml.
Our recommendations for MIC breakpoints and zone diameter breakpoints are shown in Table 3 . All proposed interpretive criteria conform to the calculated regression statistics. Given the rather low achievable levels of Ro 40-6890 in serum, the appropriate MIC breakpoints would appear to be c1 and .4 ,ug/ml for susceptibility and resistance, respectively. With these MIC breakpoints, we recommend the use of the 5-,g Ro 40-6890 disk and suggest that the following zone diameter breakpoints be used in clinical 
